

165 – 10551 Shellbridge Way Richmond, BC, V6X 2W8

BioMark Receives BIAP funding from NRC-IRAP

Vancouver, British Columbia – (March 31, 2015)–BioMark Diagnostics Inc. ("BioMark") (CSE: BUX, FSE: 20B, OTCQB : BMKDF) is pleased to announce that it has been awarded by NRC – IRAP the Business Innovation Access Program (BIAP) funding for development and optimization of its novel recombinant antibodies.

Rashid Ahmed, President and CEO, comments "This project will help optimize the potential production recombinant antibodies with work to be conducted by Dr. Bach at UBC. These antibodies will be critical in the commercial development of our cancer diagnostic kits. We are excited to be able to develop the antibodies with rich features that can help secure source and quality necessary for medical application kit development".

BioMark would like to thank both NRC and UBC for their help in this endeavor that can yield both medical and economic benefit to Canada at large.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer, early and cost effectively. BioMark is currently conducting Phase 3 multi site clinical trial for lung, breast, gastro intestinal and prostate cancers. Additionally trials related to assess response to lung cancer treatment and surgical interventions are being established.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website <u>www.thecse.ca</u>.

For further information on BioMark, please Contact:

Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. Tel. 604-282-6567 Email: <u>info@biomarkdiagnostics.com</u>

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark.

Although BioMark believes that the expectations and assumptions on which such forwardlooking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forwardlooking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.